Insulin degludec: Overview of a novel ultra long-acting basal insulin

All the basal insulin products currently available have suboptimal pharmacokinetic (PK) properties, with none reliably providing a reproducible and peakless pharmacodynamic (PD) effect that endures over 24 h from once-daily dosing. Insulin degludec is a novel acylated basal insulin with a unique mec...

Descripció completa

Dades bibliogràfiques
Autors principals: Gough, S, Harris, S, Woo, V, Davies, M
Format: Journal article
Publicat: 2013